Australian Federal Court Says Vioxx Doubles Heart Risk, Finds For Plaintiff
This article was originally published in PharmAsia News
Executive Summary
An Australian court declared Merck's Vioxx (rofecoxib) guilty of doubling the risk of heart attacks and decided for the first of 400 people in a class-action suit